Buy Rating Affirmed for Fulcrum Therapeutics: Licensing Deal with Sanofi and Promising Phase 3 Study

Fulcrum Therapeutics (FULC – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Andrew Fein from H.C. Wainwright reiterated a Buy rating on the stock and has a $17.00 price target.

Andrew Fein has given his Buy rating due to a combination of factors, one of the most significant being Fulcrum Therapeutics’ licensing agreement with Sanofi. This deal grants Sanofi the exclusive rights to commercialize Fulcrum’s losmapimod for facioscapulohumeral muscular dystrophy (FSHD) outside the United States. Fein views this partnership positively, given Sanofi’s expansive global reach and expertise in rare diseases, which complements Fulcrum’s knowledge in FSHD. The agreement also includes an initial payment to Fulcrum and the potential for additional milestone payments and royalties, which could significantly benefit Fulcrum financially. Additionally, such licensing deals can sometimes be precursors to mergers and acquisitions, which presents another potential upside for the company.

Moreover, the anticipated release of top-line data from the Phase 3 REACH study in the fourth quarter of 2024 is a pivotal event for Fulcrum. This study, which has enrolled a sufficient number of patients to increase confidence in its results, could validate losmapimod’s efficacy for FSHD, a condition with no approved therapies and a high unmet medical need. Fein also notes that the design of the trial, informed by a previous Phase 2 study, has multiple chances to demonstrate the drug’s positive impact. Alongside this, Fein believes that the company’s developments in treating sickle cell disease with pociredir are not fully appreciated by the market, adding another layer of potential value to Fulcrum’s pipeline. The ongoing adjustments and expansions in their clinical trials aim to target a more advanced patient population, indicating a thorough and adaptive research approach.

Fein covers the Healthcare sector, focusing on stocks such as Amylyx Pharmaceuticals Inc, Blueprint Medicines, and Foghorn Therapeutics. According to TipRanks, Fein has an average return of 12.0% and a 48.78% success rate on recommended stocks.

In another report released yesterday, Stifel Nicolaus also maintained a Buy rating on the stock with a $22.00 price target.

TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.

Fulcrum Therapeutics (FULC) Company Description:

Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It develops new medicines and focuses on unlocking gene control mechanisms to develop small molecule therapies. Its product candidate includes Losmapimod and FTX-HbF. The company was founded by Michael R. Green, Danny Reinberg, Rudolf Jaenisch, Jeannie T. Lee, and Bradley E. Bernstein on August 18, 2015 and is headquartered in Cambridge, MA.